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Accurate mass measurements are often used in the structural determination of unknown
compounds of low molecular mass (i.e., below 500 Da). Recently, it has been shown that
accurate mass measurements also can be made on small denatured proteins (i.e., Mr, 17,000)
to confirm their amino acid composition and identify the presence of isoforms. In the current
report, we present nondenaturing electrospray (ES) mass spectrometry data on the direct
accurate mass measurement of ligands in complex with the retinoid X receptor ligand binding
domain (RXR LBD; Mr 31,370.92). Average mass errors were below 0.198 Da, 6.3 ppm
(standard deviation [SD], 0.146; n 10) for low-affinity fatty acid agonists analyzed in complex
with the RXR LBD. Protein consumption was less than 15 pmol, with fatty acid ligands present
at concentrations corresponding to their median effective concentration value (low micromo-
lar, determined in transfection assays). Although determination of fatty acid mass was only
sufficiently accurate to give nominal mass values, measurements were of sufficient accuracy to
assign fatty acid chain length, degree of unsaturation, or cyclization. Using 17-estradiol as a
control, the ability to observe specific ligand binding is shown for both high- and low-affinity
RXR agonists. In addition, binding of a novel synthetic receptor agonist XCT0315908 to the
RXR LBD is reported. This compound showed a high degree of complex formation, and the
receptor–ligand complex could be mass measured with an average mass error of 0.024 Da,
0.8 ppm (SD, 0.092; n  9). Thus, specific binding of both nanomolar and micromolar affinity
ligands to a nuclear receptor LBD can be directly observed using nondenaturing ES mass
spectrometry and accurate mass measurements additionally can be made on intact complexes
in the same experiment. This methodology also is applicable when ligands are present as
components of mixtures. (J Am Soc Mass Spectrom 2005, 16, 1631–1640) © 2005 American
Society for Mass SpectrometryThe value of accurate mass measurements hasbeen known to the mass spectrometry commu-nity for 50 y [1]. For masses below 500 Da, the
number of unique elemental compositions correspond-
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doi:10.1016/j.jasms.2005.06.003ing to a given mass value is limited, and from a mass
measurement made to an accuracy of 5 ppm an
elemental composition can be deduced when valence
rules and additional chemical information is considered
[2– 4]. Traditionally, accurate mass measurements on
low molecular weight organic molecules have been
performed using high-resolution double-focusing mag-
netic-sector instruments [2, 4 –9], although Fourier-
transform ion-cyclotron-resonance (FTICR) instruments
[10] and orthogonal-acceleration time-of-flight (OA-
TOF) instruments [11–15] also are currently being used
for this application. Magnetic-sector instruments have
been manufactured with the capability of achieving
resolutions in excess of 100,000 (10% valley definition)
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instruments can achieve resolutions in excess of 200,000
(full-width at half-maximum-height [FWHM] defini-
tion) in the electrospray (ES) analysis of large biomol-
ecules [10]. Such a resolution is sufficient to resolve the
isotopic peaks of large multiply charged proteins and
even isotope fine structure, that is, peaks corresponding
to species of different elemental compositions [17, 18].
Although the application of FTICR mass spectrometry
is becoming increasingly widespread, until very re-
cently the technique has required a considerable degree
of operational skill, and it is only now that the FTICR
mass spectrometer is becoming an instrument of choice
in biological mass spectrometry laboratories.
Although often considered together, high-resolution
is not synonymous with accurate mass [19], and, in fact,
the realization by Beynon in 1954 of the value of
accurate measurements for the determination of ele-
mental composition was first made with data produced
by a single-focusing magnetic-sector instrument capa-
ble of only modest resolution (250, 10% valley defini-
tion) [1]. It should be remembered, however, that if the
accurate mass of a compound is to be reliably deter-
mined, it is necessary to work with sufficient resolution
so that homogenous peaks are mass measured. Quad-
rupole instruments operated at unit mass resolution
have produced accurate mass data on ES ionized pure
compounds [20], and, currently, OA-TOF instruments
are widely used in both chemistry and biochemistry
laboratories for accurate mass measurements [11–15].
The popularity of OA-TOF instruments is a conse-
quence of their high sensitivity, moderately high resolv-
ing power, and, perhaps most importantly, ease of
operation [11].
The accurate mass of a protein is an important but
often difficult to measure, property [21]. An accurate
determination of protein mass gives information on
posttranslational modifications (e.g., disulfide bridges
or polymorphisms) [8, 21]. Recently, Rai and coworkers
have demonstrated the accurate mass measurement
(i.e., the abundance-weighted average-mass centroid,
obtained after data processing) of human hemoglobin
(Hb) variants using a triple quadrupole instrument [22].
The authors used the normal -chain Hb peaks present
in the Hb mass spectrum for internal calibration of the
mass scale. Through optimization of the number of data
points sampled per m/z unit and the input parameters
of the data analysis process, it was possible to detect
heterozygous -chain Hb variants, even when they
were unresolved from the normal -chain Hb and
differed in mass by only 1 Da.
In the current study we have focused our attention on
the mass spectrometric measurement of nuclear receptor
(NR)–ligand complexes. NRs are ligand-activated tran-
scription factors [23], and studies of the noncovalent
interactions between NRs and their ligands using ES mass
spectrometry have been reported [24 –28]. We have previ-
ously investigated the binding of fatty acids to the retinoid
X receptor  (RXR, NR2B1) ligand binding domain(LBD) using nondenaturing ES mass spectrometry [28].
Fatty acid–receptor complexes were observed but
were not analyzed with sufficient mass accuracy to
allow the degree of fatty acid unsaturation to be
determined directly. This was a significant drawback
of that study because ligand binding (and activity) is
related to the degree of fatty acid unsaturation [29].
Several NR subfamilies have been shown to be
involved in lipid metabolism, for example, peroxisome-
proliferator-activated receptors [30], liver X receptors
[31, 32], and farnesoid X receptors [33, 34], and it has
been shown that RXR can bind to and be activated by
free fatty acids [29, 35–37]. NRs including orphan
receptors, that is, receptors with as yet unidentified
ligands [38], are regarded as important potential drug
targets, and the identification and characterization of
ligands for NRs is highly relevant to the pharmaceutical
industry. One possible way to identify such ligands is
by the use of nondenaturing ES mass spectrometry to
measure the mass of receptor–ligand complexes [39].
Although several examples of the use of ES mass
spectrometry to show ligand binding to NRs have been
reported, there is always a doubt as to the specificity of
the observed interactions. Thus, one of the goals of the
current study was to show that the receptor–ligand
binding observed by mass spectrometry was indeed
specific. In addition, this study aimed at maximizing
the degree of mass accuracy obtainable in the direct
measurement of bound-ligand mass. Noncovalent com-
plexes between the human RXR LBD (relative molec-
ular massMr 31,370.92) and the unsaturated fatty acids,
docosahexaenoic acid (DHA, C22:6), oleic acid (C18:1),
and linolenic acid (C18:3), as well as synthetic agonists
LG268 and XCT0315908, were used as a model system.
The fatty acids are low-affinity ligands that have been
shown to activate the RXR in transfection studies [36]
and bind to the RXR LBD by nondenaturing ES mass
spectrometry [28]. The synthetic agonist XCT0315908
specifically activates RXR in the context of the RXR -
Nurr1 (NR related 1, NR4A2) heterodimer [40], but to
our knowledge, direct binding of this compound to the
RXR LBD has not been shown.
Experimental Procedures
Reagents and Solutions
Oleic acid (cis-9-octadecenoic acid, C18:1), cis-4,7,10,13,
16,19-DHA (C22:6), and 17-estradiol (E2) were from
Sigma-Aldrich Sweden AB (Stockholm, Sweden).
LG268 was from Tularik, Inc. (South San Francisco,
CA). Linolenic acid (cis-9,12,15-octadecatrienoic acid,
C18:3) was from Larodan Fine Chemicals AB (Malmö,
Sweden). XCT0315908 was from X-Ceptor Pharmaceu-
ticals, Inc. (San Diego, CA). Ligand stock solutions (10
mM) were prepared in 99.5% ethanol except for
XCT0315908, which was prepared in 90% ethanol, 10%
dimethylsulfoxide (DMSO). Milli-Q-purified deionized
water was used for all buffers.
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Human RXR LBD, amino acids 203-462, was expressed
as a His6-tag fusion protein in Escherichia coli and
purified under nondenaturing conditions in the absence
of ligand. Purified protein was dialyzed against 50 mM
of ammonium acetate, pH 8, and aliquots were frozen at
80 °C until analyzed. To asses the functionality of the
expressed protein, the RXR LBD construct also was
purified in the presence of 9-cis-retinoic acid and ana-
lyzed by analytical size-exclusion chromatography es-
sentially as described by Egea et al. [41]. The agonist
induced a significant reduction in the amount of apo-
tetrameric RXR LBD and in the formation of the dimeric
holo-protein. This is in accordance with previously
published results for the behavior of RXR LBD in
solution [41– 43] and shows that the expressed protein is
fully functional with respect to ligand binding and
multimerization.
Mass Spectrometry
Data were acquired on a Micromass QTOF Ultima mass
spectrometer, (Micromass Plc., Manchester, UK) equipped
with a Z-spray source, operated in the positive-ion mode
under the control of MassLynx v3.5 software (Micromass,
Manchester, UK). The capillary voltage was 3.0 kV. The
source block temperature was set to 120 °C to promote
solvent evaporation. The desolvation gas flow was 210
L/h at a temperature of 100 °C. To maintain receptor–
ligand noncovalent complexes, it was necessary to opti-
mize the source offset voltage potentials; specifically the
“rf lens” and “cone voltage” settings were optimized
between 16.0 and 20.0 V and 31 and 35 V, respectively. The
pumping to the ES interface regionwas throttled, bringing
the reading on the “backing” Pirani vacuum gauge up
from 1.8 to 2.0 mbar [44]. (In subsequent work using the
QTOF Ultima instrument we have found that increasing
the source pressure is nonobligatory to maintain NR—
ligand complexes.) The collision cell was pressurized
using argon, and the collision voltage was set to 5.0 V
unless otherwise indicated. The instrument was operated
in single reflectron mode at a resolution of 11,000
(FWHM definition).
Sample Analysis
Protein stock solution (158 pmol/L of RXR LBD
and 50 mM of ammonium acetate, pH 8) was diluted
158-fold in 10 mM of ammonium acetate, pH 8, to give
a protein concentration of 1 pmol/L. The 10 mM of
ammonium acetate buffer was freshly prepared to mini-
mize the degree of ammonium acetate adducts to the
protein. The apo-RXR LBD protein (1 pmol/L, 10 mM
ammonium acetate, pH 8) was analyzed before all pro-
tein–ligand analyses and the dominant species was found
to correspond to the [M  13H]13 to [M  11H]11 (13
to 11) charged states of the monomeric protein, forming
a peak envelope in the 2400-2900 m/z range (Figure 1a).For ligand binding experiments, test compound
stock solution (10 mM in 99.5% ethanol or 9:1 ethanol/
DMSO) was added to give a fivefold excess of ligand to
protein (i.e., 5 pmol/L of test compound). For the
analyses of fatty acid mixtures each fatty acid was
added to give a concentration of 2.5 pmol/L (total
fatty acid concentration of 5 pmol/L). Samples were
vortexed and left to equilibrate for at least 15 min. at
room temperature before starting sample infusion. The
sample was delivered to the ES interface at a flow rate
of 5 L/min using a Harvard syringe pump. Data were
acquired over the m/z range 1000-4500 until 1000
counts were obtained for the least abundant ion of
interest, that is, any of the 13 to 11 charge states of
the apo- or holo-RXR LBD species, to give satisfactory
ion statistics. Mass measurements were performed after
averaging 35 or 100 scans (5-s scan time).
Internal Mass Calibration
Data analysis was performed using the MassLynx v3.5
software package supplied by the instrument manufac-
turer and was essentially as previously described [22].
Briefly, each raw spectrum (m/z range, 2350-2950, en-
compassing the 13 to 11 charge states) was first
background subtracted using a 25th order polynomial
such that 5% fell below the new base line. The sub-
Figure 1. ES mass spectra (raw data) of agonists and a nonago-
nist after addition to RXR. (a) RXR LBD (1 pmol/L) alone; or
in the presence of 5 pmol/L of (b) DHA, (c) LG268, or (d) E2. The
[M  13H]13 to [M  11H]11 charge state are shown in each
spectrum.tracted spectrum was smoothed (2  20 channels,
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the subtracted and smoothed peaks were obtained
using 20% of the peak top and a minimum peak width
setting of 45 channels (determined empirically to be
suitable given the peak width of the RXR LBD and its
ligand–complex peaks). Internal calibration was per-
formed using a single-order polynomial and apo-RXR
LBD peaks (i.e., the 13 to 11 charge states). Note that
the number of data points per m/z was the standard 16
data points for the acquired data, which is the maxi-
mum when the standard MassLynx software is used.
Mass Measurement
Each background subtracted spectrum (m/z range, 2350-
2950) was deconvoluted onto a true mass scale using
the maximum entropy-based Maxent 1 function of the
MassLynx software package [45, 46]. The processing
parameters were “output mass range” of 31,000-32,500
Da at a “resolution” of 0.1 Da/channel; the “simulated
isotope pattern” model was used with the “spectrum
blur width” parameter set to 0.2 Da; the “minimum
intensity ratios” between successive peaks were 20%
(left and right). Each deconvoluted spectrum was then
smoothed (2  3 channels, Savitzky-Golay smooth) and
the mass centroid values were obtained using 90% of
the peak top and a minimum peak width at half height
of 45 channels. The mass of the bound ligand was
obtained by subtracting the measured mass value for
the apo-protein (apo-RXR) from the measured mass of
the receptor–ligand complex (holo-RXR).
Results and Discussion
Specificity of Ligand Binding
The RXR has been shown to be activated by the
polyunsaturated fatty acid DHA (Mr 328.49, all Mr
values were calculated from data from Ref. [47]) [36].
The receptor–ligand complex formed between this low-
affinity agonist and the RXR LBD is clearly observed
by peaks at m/z 2439.43, 2642.64, and 2882.83, corre-
sponding to the 13 to 11 charge states of the com-
plex (Figure 1b). The high-affinity agonist LG268 (Mr
363.49) forms a more stable complex with the RXR
LBD than does DHA, as is indicated by the more intense
peaks for the holo-receptor (m/z 2442.10, 2645.56 and
2885.96, Figure 1c) relative to the apo-receptor. It should
be noted that the intensity of holo-receptor peaks is a
reflection of both the gas-phase and solution-phase
receptor–ligand binding affinity.
A solution containing E2 (Mr 272.39) and the RXR
LBD was analyzed in a control experiment. The result-
ant mass spectrum (Figure 1d) was similar to that of the
apo-RXR sample (Figure 1a) but does show a minor degree
of receptor–lipid complex formation. A minor peak is
observed at m/z 2637.88, corresponding to the 12 charge
state of the complex (Figure 1d). This indicates a degree of
nonspecific protein–lipid binding, but the intensity ofprotein–E2 peaks are much lower than those that corre-
spond to specific receptor–ligand binding between RXR
LBD and the two agonists (Figure 1b, c).
High-Accuracy Mass Measurement of Receptor
Bound Ligands
By averaging 35 mass scans (5 s/scan), spectra were
obtained with sufficient signal-to-noise ratio to allow
the accurate mass determination of the holo-RXR LBD
complex with DHA (Figure 2a) and with the two other
unsaturated fatty acids, that is, oleic acid and linolenic
acid (C18:1, Mr 282.47; and C18:3, Mr 278.44; data not
shown). The two C-18 unsaturated fatty acids have been
shown to activate the RXR in transfection experiments
but with lower efficacy than DHA [36, 37]. Shown in
Figure 2a is a representative background subtracted
and internally calibrated spectrum (35 scans of raw
data, not smoothed) of a 1-pmol/L RXR solution
with an excess of DHA added (5 pmol/L). The RXR–
DHA complex is observed by peaks at m/z 2439.48,
2642.63, and 2882.80 for the three charge states, 13 to
11. Gluconoylated apo- and holo-protein is indicated
by peaks labeled by filled circles. Shown in Figure 2b is
the corresponding deconvoluted spectrum. For accurate
mass measurements, the deconvoluted spectrum is sub-
sequently smoothed and centroided to obtain the apo-
and holo-RXR accurate mass values. The masses of the
bound ligands were determined to be Mr 328.69 (DHA,
standard deviation [SD], 0.07; n  12), Mr 282.62 (C18:1,
SD, 0.08; n  10) andMr 278.44 (C18:3, SD, 0.19; n  10;
Table 1). These values correspond to average mass-
measurement errors of 0.20, 0.16, and 0.002 Da, corre-
sponding to 6.3, 5.1, and 0.06 ppm in the respective
receptor–ligand complexes (Table 1). Shown in Table 1
also are the SDs of the measured mass values for holo-
and apo-RXR species (columns F and G). It is notewor-
thy that the SDs for the holo-complexes are always
higher than those for the apo-protein.
The fact that the RXR can be activated by a number of
unsaturated fatty acids [36, 37] highlights the importance
of performing experiments in which the receptor can
potentially interact with more than one ligand. Initially,
the simplest experiment was performed in which an
equimolar mixture of DHA and oleic acid was added to
the RXR LBD sample solution to give a final concentra-
tion of 2.5 pmol/L of each fatty acid. Both fatty acids
formed a complex with RXR LBD and the masses of the
ligands were measured to beMr 328.66 andMr 282.49 (SD,
0.15 and 0.12, respectively; n  13). These measured
values corresponded to mass measurement errors of 0.17
Da (DHA) and 0.02 Da (oleic acid; Figure 2c, d; Table 1).
Differentiation Between RXR LBD Binding
to a Single Ligand or to Multiple Ligands
For the analyses of complex mixtures containing more
than one potential ligand, a problem to be confronted is
BD i
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sufficiently close in mass so that resolution of holo-
protein peaks on the m/z scale will be impossible. To
investigate the possibility of analyzing such unresolved
ligand–protein complexes and to observe their effect on
the mass measurement of the holo-protein, we analyzed
linolenic (mr 278.44) and oleic acid (Mr 282.47), initially
Figure 2. The unsaturated fatty acids DHA a
subtracted raw data spectra (35 scans) of RXR L
of DHA; or (c) a 2.5-fold excess each of DHA an
charge states are shown. (b and d, respectively)
after internal calibration. Gluconoylated RXR L
Table 1. Determination of the mass of polyunsaturated fatty aci
(35 or 100 scans were averaged for each mass measurement as in
A
B C
Compound
Average,
observed Mr
SD, observed
Mr
36 Scans
DHA (n  12) 328.693 0.074
Oleic acid (n  10) 282.623 0.083
Linolenic acid (n  9) 278.437 0.186
DHA  oleic acid
(n  13)
DHA 328.662 0.145
oleic acid 282.489 0.122
100 Scans
Linolenic acid
(n  10)
278.410 0.147
Oleic acid (n  9) 282.323 0.098
Linolenic  oleic acid
(n  10)
280.567 0.244 28The table shows, by column, the average of the measured Mr values (B); the
mass error for each compound (E); and the SDs of the holo-RXR and apo-Rby adding each acid separately to the protein and then
as an equimolar mixture (Figure 3a– c, 700-1000 scans/
spectrum, 5 s/scan). When the apo-receptor peaks from
the three experiments were superimposed they were
found to almost exactly coincide (Figure 3d), indicating
that any drift of the instrument mass scale over the
course of the experiment was negligible (in Figure 3 all
leic acid bind to the RXR LBD. (a) Baseline
pmol/L) with the addition of a fivefold excess
ic acid. The m/z ranges covering the 13 to 11
corresponding deconvoluted spectra are shown
s indicated by a filled circle in panels a–d.
ands when part of RXR LBD–fatty acid noncovalent complexes
ed).
D
E F G
Theoretical Mr
Average
error
SD
holo-RXR
SD
apo-RXR
328.495 0.198 0.119 0.070
282.467 0.156 0.137 0.085
278.435 0.002 0.232 0.068
328.495 0.167 0.164 0.069
282.467 0.022 0.166 0.069
278.435 0.025 0.203 0.07
282.467 0.143 0.133 0.091
 (278.435  282.467)/2 0.116 0.131 0.133nd o
BD (1
d ole
Thed lig
dicat
0.451SD of those measurements (C); theoretical Mr values (D); the average
XR (F and G, respectively) measurements.
oleni
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contrast, the holo-receptor peaks from the three experi-
ments did not coincide. It is evident that for the holo-
receptor complex, introduction of an additional two
double bonds to the C18:1 template causes a distinct
translocation of the [M  12H]12 peak (Figure 3e).
When an equimolar mixture of the two ligands was
analyzed, the working resolution of the instrument was
insufficient to resolve the two holo-receptor complexes
(Figure 3e). However, the holo-receptor complex was
found to give a peak that was centered amid the two
individual holo-receptor peaks. This is illustrated further
in Figure 4, where individual experimental measurements
of ligand mass are plotted (100 scans, 5 s/scan) after
incorporation of 5 pmol/L of either oleic acid (C18:1,
labeled by filled circles), linolenic acid (C18:3, labeled by
filled squares), or an equimolar mix of the two (“mix,”
labeled by filled triangles). In these experiments, the
average of the measured ligand Mr values were 282.32
Figure 3. Analysis of unresolved receptor–ligan
5 s/scan) of RXR LBD, 1 pmol/L in the prese
acid (C18:1), 5 pmol/L; and (c) a mixture of b
pmol/L are shown without internal calibratio
showing the (d) apo- and the (e) holo-receptor pea
are in light-grey fill, linolenic acid peaks are in
corresponding to mixed binding of oleic and lin(SD, 0.10; n 9) and 278.41 (SD, 0.15; n 10), respectively,for oleic acid and linolenic acid when analyzed separately.
For the mixture analyses, the average measuredMr of the
bound ligands was 280.57 Da (SD, 0.25; n 10). This mass
value is approximately the mean mass of the two ligands,
indicating that both ligands are bound with an approxi-
mately equal overall affinity (i.e., combined solution and
gas-phase affinity) to the receptor.
As a possible means for identifying the binding of
multiple ligands close in mass, the peak width of
holo-RXR complexes were compared. The FWHM of
the C18:1 and C18:3 holo-receptor peaks were 1.28 and
1.37 Da, respectively. For the mixture of ligands, the
peak width increased to 1.59 Da.
Binding of XCT0315908 to RXR LBD
The synthetic ligand XCT0315908 (Mr 345.40) has been
identified as an RXR agonist [40]. However, direct in
vitro binding to the RXR LBD has not been shown
plexes. Mass spectra (raw data, 700-1000 scans,
of (a) linolenic acid (C18:3); 5 pmol/L (b)oleic
oleic acid, 2.5 pmol/L, and linolenic acid, 2.5
perimposed raw data spectra from panels a–c,
r the 12 charge state. (d and e) Oleic acid peaks
grey fill, and the outline of the holo-RXR peak
c acid is indicated by a black line (in panel e).d com
nce
oth
n. Su
ks fo
dark-previously. Therefore, this compound was analyzed
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of ligand to protein, the formation of RXR -
XCT0315908 complex was observed giving peaks m/z
2440.79, 2644.25, 2884.52, and 3172.72 for the 13 to 10
charge states (Figure 5a). The shift of the peak-envelope
maximum to higher m/z (i.e., 11 rather than 12) may
be an effect of the presence of DMSO added as part of
the ligand stock solution. This effect has been observed
previously [27]. The average measured mass of the
ligand was 345.37 Da (SD, 0.09; n  9), which corre-
sponds to a mass measurement error of 0.024 Da.
Sample Consumption and Ligand Concentration
Because of the high sensitivity of quadrupole TOF-type
instruments, native protein samples (i.e., from aqueous
solutions of near-neutral pH) can be readily analyzed at
concentrations of 1 pmol/L. To obtain high-quality
data necessary to make accurate mass measurement on
the receptor–ligand complexes, spectra were accumu-
lated for at least 3 min, but the total consumption of
sample was always less than 15 pmol. In the ligand
binding experiments the ligand concentration used was
5 pmol/L, which corresponds to the median effective
concentration (EC50) value for unsaturated fatty acids
activating RXR [36, 37].
Discussion
The concept of using the natural affinity of a receptor
protein for its cognate ligand to identify novel ligands
from compound mixtures has, for many years, been at
the basis of pharmaceutical screening and development
programs. The analytical methods used have relied on
the capacity of a “new” ligand to displace a predefined
high-affinity ligand or on the recruitment of coactivator
peptides by the receptor on ligand binding [48]. For true
orphan receptors, for which there is an absence of
known ligands and also interacting proteins partners, a
direct method for detecting and identifying receptor–
Figure 4. Individual experimental mass measurements (100
scans) of oleic acid (filled circles), linolenic acid (filled squares),
and an equimolar mixture of the two fatty acids (filled triangles).
For the fatty acids the theoretical Mr values are indicated by solid
lines. Analysis performed as in Figure 3.ligand complexes would be extremely valuable. Inrecent years, nondenaturing ES mass spectrometry has
evolved to the point where noncovalent interactions are
analyzed routinely [49], and in the current study we
have used this methodology to investigate receptor–
ligand complexes. We also have explored the possibility
of determining the molecular weight of receptor–ligand
complexes with a high degree of mass accuracy, be-
cause such measurements can then lead to a direct
measurement of the mass of the bound ligand. Addi-
tionally, we have considered the question of binding
specificity, in particular, the extent to which binding
specificity can be retained in the ES mass spectrometry
process.
RXR high- and low-affinity agonist ligands and in
control experiments, a lipid with no known affinity for
RXR were analyzed for binding to the receptor LBD.
The agonists were shown by ES mass spectrometry to
bind to the RXR LBD (Figures 1b, c; 2; 3a, b; and 5a).
However, it should be emphasized that agonist efficacy
is based both on the affinity of the ligand for the
receptor and also on its ability to form productive
protein contacts to stabilize the receptor–coactivator
Figure 5. The novel agonist XCT0315908 binds to the RXR LBD.
(a) A raw mass spectrum of the m/z range encompassing the major
monomeric RXR charge state envelope (13 to 10) for a
solution of 5 pmol/L of XCT0315908 and 1 pmol/L of RXR.
(b) and (c) The structures of the high-affinity RXR agonist LG268
and XCT0315908, respectively.
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between the difference in the EC50 values of the agonists
LG268 (nanomolar EC50) and DHA (micromolar EC50)
and the more modest difference in the peak intensities
for the holo-receptor complexes as observed by ES mass
spectrometry (Figure 1b, c). A minor degree of nonspe-
cific binding was found to occur in the ES experiments,
as is evident from the observation of a low-intensity
peak corresponding to the RXR–17-estradiol complex
(Figure 1d). This was not an unsurprising result, be-
cause during the repeated droplet fission events of the
ES process, solvent is removed and surface-active com-
ponents such as E2 become disproportionally enriched
in the ultimate ion-forming droplet. High E2 concentra-
tions in these droplets may then be the cause of the
nonspecific binding being observed. However, clearly,
the degree of nonspecific binding is much less than the
binding of any RXR agonist compound to RXR (cf.
Figure 1d with 1b and 1c). It also should be noted that
nonspecific binding could be identified by performing a
simple ligand exchange experiment, in which a high-
affinity ligand is added to the solution containing the
supposed nonspecifically bound ligand. If the binding
is nonspecific, addition of a high-affinity ligand will
simply elevate the mass of the complex by an amount
equivalent to that of the added high-affinity ligand. If,
alternatively, binding of the first ligand to the protein
were specific and the first ligand is displaced by the
second high-affinity ligand, the mass of the complex
will be shifted by an amount equivalent to the differ-
ence in mass between the first and second ligand [28].
The main objective of the current study was to
investigate whether the mass of receptor–ligand com-
plexes could be measured with high mass accuracy. As
with small molecules, the mass of denatured proteins
can be measured with high accuracy. For example, Rai
et al. have eloquently described a method for the
accurate mass measurement of Hb variants [22]. For
such measurements high resolution was not required,
and rather than measuring a monoisotopic mass, Rai et
al. determined an accurate abundance-weighted mass
(average mass, Mr) for the Hb variants. In the current
study we have applied a similar methodology to that of
Rai et al. but used nondenaturing ES to determine the
accurate mass of receptor–ligand complexes.
In experiments to determine an accurate Mr value of
a receptor–ligand complex, the determination of the
abundance-weighted peak centroid of the unresolved
isotopic envelope is the critical measurement. This
measurement will be influenced by peak shape. This is
not a problem if the peak is Gaussian and drops to
baseline, as is the case with a homogeneous peak from
a pure denatured protein [19]. However, when analyz-
ing proteins under nondenaturing conditions these cri-
teria are less well adhered to. In the current study the
accurate mass of the holo-receptor protein was deter-
mined using the apo-receptor protein as an internal
calibrant. In this case any differences in peak shape
between the two sets will have a significant effect onmass measurement accuracy. To minimize this poten-
tial problem, it was necessary to optimize carefully the
data-processing steps used in the mass determination
process. Although any drastic differences in peak shape
in the analyzed data were not immediately obvious,
such factors may account for discrepancies between
observed and theoretical mass values, as well as affect-
ing the SD of these measurements. Most notably, there
was an increased SD in the mass measurement of the
holo-receptor from the mixture of oleic and linolenic
acids (0.24 Da), as compared with that for the holo-
receptor when measured for the acids individually
(0.098 and 0.15 Da; Figure 3 and Table 1). This is
explained by the holo-receptor peak shape for a mixture
of unresolved competing ligands being less well de-
fined than for a homogeneous peak. Ion addition, the
SD for the holo-RXR mass measurements were always
higher than for the corresponding measurements of the
apo-protein (Table 1, columns F and G). This can be
rationalized in part by a greater influence of baseline
variations on the holo- compared with apo-receptor peak
shape (see, e.g., Figure 2a), that is, the holo-receptor
peaks will tend to be less well defined. Despite using
the apo-protein for internal calibration, its measured
mass requires correction to obtain the full accuracy and
precision. This is partly due to the mass being critically
dependent on the peak width, which tends to change
slightly over a series of analyses made over several
hours [22]. Although reprocessing a given data set by
MaxEnt could be undertaken to make the apo-protein
mass equal its sequence mass by adjusting the peak
width parameter, this is not necessary in the current
study because all that is required is a simple measure-
ment of the mass difference between the holo- and
apo-protein to give the ligand mass.
Because the amino acid sequence of the recombinant
RXR LBD protein is known, the nonliganded protein
peaks in the mass spectrum were used for internal
calibration. Each mass spectrum was independently
calibrated, thereby reducing the influence of external
factors such as temperature changes on the accuracy of
the mass measurement. The mass measurement errors
of 0.2, 0.16, and 0.002 Da for DHA, oleic acid, and
linolenic acid, respectively (Table 1), corresponds to
accuracies of 6.3, 5.1, and 0.06 ppm for the receptor–
ligand complexes. This degree of mass accuracy allows
the bound ligand mass to be determined to better than
0.2 Da. Although nowhere near sufficient for the assign-
ment of a unique elemental composition to the ligand,
this degree of mass accuracy allows chain length and
degree of unsaturation (or cyclization) to be determined
if the class of ligand being investigated is known (fatty
acid) and is relevant in the testing of complex ligand
mixtures such as a combinatorial library comprised of
known components. It should be noted that in the best
case (i.e., an average mass error of 0.002 Da for linolenic
acid) the observed mass error is only 7.3 ppm of the
ligand mass.
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was used to show the binding of a novel synthetic
agonist XCT0315908 to the RXR LBD. In terms of
holo-receptor peak intensity, receptor occupancy ap-
pears to be slightly lower than for DHA (cf. Figures 5a
and 1b). It is clear, however, that the XCT0315908 is
behaving like an RXR ligand because the relative inten-
sity of the holo-RXR peaks are far greater than for the
RXR nonagonist E2 (cf. Figures 5a and 1d). Binding of
XCT0315908 within the ligand binding pocket (LBP) of
RXR is likely given the overall structural similarity be-
tween LG268 (a high-affinity RXR agonist) and
XCT0315908 (Figure 5b, c), where the anchoring of LG268
in the LBP is by ionic interaction between the carboxylic
acid group and a conserved arginine residue [29].
A final comment is required on the feasibility of the
current methodology to observe ligand binding from a
solution containing multiple closely related (in mass)
potential ligands. Empirically, a holo-RXR peak involv-
ing single ligand binding can be expected to have a
FWHM of 1.3 Da, while that of a holo-RXR peak
corresponding to mixed binding of two similar affinity
ligands differing in mass by 4 Da will have a FWHM of
1.6 Da. The exact width and center of the peak will
depend on the relative affinity of the ligands and their
exact mass. However, the observation of peak broaden-
ing will alert the investigator to the possibility of
multiple ligand binding.
In conclusion, the results of the current study show
that nondenaturing ES mass spectrometry can be used
to determine the mass of binding ligands with sufficient
accuracy to provide information on their structure.
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